MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-05-2025
AxoGen EBITDA 2011-2026 | AXGN
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA AxoGen
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.18 M | -17.2 M | -26.9 M | -22.7 M | -21.7 M | -28.5 M | -19.6 M | -7.38 M | -7.69 M | -9.02 M | -9.6 M | -9.45 M | -7.49 M | -6.63 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.18 M | -28.5 M | -13.6 M |
Quarterly EBITDA AxoGen
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.33 M | 67 K | - | 1.34 M | 1.23 M | -3.04 M | - | -2.87 M | -6.1 M | -6.63 M | - | -4.09 M | -7.21 M | -10.6 M | - | -4.63 M | -6.52 M | -5.45 M | - | -671 K | -7.94 M | -8.2 M | - | -5.92 M | -7.44 M | -9.99 M | - | -4.64 M | -4.62 M | -4.81 M | - | -1.37 M | -1.34 M | -3.09 M | - | -919 K | -1.44 M | -2.54 M | - | -1.78 M | -2.07 M | -2.5 M | - | -1.69 M | -2.23 M | -2.96 M | - | -2.22 M | -2.15 M | -2.3 M | - | -1.9 M | -1.48 M | -1.89 M | - | -2.41 M | -1.3 M | -827 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.33 M | -10.6 M | -3.31 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B |  USA |
 |
Abiomed
ABMD
|
254 M | - | - | $ 17.2 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
8.53 M | $ 9.76 | 1.99 % | $ 701 M |  Israel |
 |
Acutus Medical
AFIB
|
-11.5 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | USA |
 |
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | USA |
 |
Apyx Medical Corporation
APYX
|
-16.6 M | $ 3.92 | 12.33 % | $ 136 M | USA |
 |
Alphatec Holdings
ATEC
|
-57.8 M | $ 17.97 | -20.68 % | $ 2.57 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | USA |
 |
Bio-Rad Laboratories
BIO
|
421 M | $ 322.91 | -0.16 % | $ 9.11 B | USA |
 |
Bruker Corporation
BRKR
|
437 M | $ 53.33 | -2.07 % | $ 7.95 K | USA |
 |
BioSig Technologies
BSGM
|
-12.7 M | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
3.87 B | $ 95.53 | -2.13 % | $ 141 B | USA |
 |
EDAP TMS S.A.
EDAP
|
-18 M | $ 4.1 | 11.41 % | $ 153 M |  France |
 |
Abbott Laboratories
ABT
|
8.16 B | $ 124.29 | -1.27 % | $ 216 B | USA |
 |
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | USA |
 |
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | USA |
 |
CONMED Corporation
CNMD
|
217 M | $ 43.45 | 1.31 % | $ 1.34 B | USA |
 |
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | USA |
 |
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | USA |
 |
Cutera
CUTR
|
-148 M | - | -10.19 % | $ 1.99 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
Integra LifeSciences Holdings Corporation
IART
|
70.8 M | $ 13.09 | -3.61 % | $ 1.01 B | USA |
 |
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | USA |
 |
Dynatronics Corporation
DYNT
|
-1.97 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
-106 M | - | - | $ 10.2 M | USA |
 |
Electromed
ELMD
|
10.7 M | $ 28.66 | -0.49 % | $ 242 M | USA |
 |
IRIDEX Corporation
IRIX
|
-8.91 M | $ 1.49 | 29.56 % | $ 24 M | USA |
 |
InMode Ltd.
INMD
|
113 M | $ 14.49 | 0.35 % | $ 1.15 B | Israel |
 |
Second Sight Medical Products
EYES
|
-24.3 M | - | -0.97 % | $ 54.4 M | USA |
 |
Align Technology
ALGN
|
753 M | $ 171.78 | -0.58 % | $ 12.9 B | USA |
 |
Accuray Incorporated
ARAY
|
14 M | $ 0.88 | -0.46 % | $ 90.4 M | USA |
 |
IRadimed Corporation
IRMD
|
22.8 M | $ 97.57 | -1.39 % | $ 1.24 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-15.9 M | $ 20.12 | 9.89 % | $ 464 M | USA |
 |
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
-18.8 M | $ 15.66 | 4.96 % | $ 423 M | USA |
 |
FONAR Corporation
FONR
|
9.84 M | $ 18.6 | 0.27 % | $ 122 M | USA |
 |
GBS
GBS
|
-9.67 M | - | -0.57 % | $ 7.12 M | USA |
 |
Pulmonx Corporation
LUNG
|
-56.6 M | $ 2.0 | -2.21 % | $ 78.2 M | USA |
 |
Globus Medical
GMED
|
420 M | $ 91.33 | -3.28 % | $ 12.4 B | USA |
 |
Aziyo Biologics
AZYO
|
-26.8 M | - | 1.37 % | $ 20.5 M | USA |
 |
Myomo
MYO
|
-10.5 M | $ 0.99 | 0.29 % | $ 6.98 M | USA |
 |
Establishment Labs Holdings
ESTA
|
-45.3 M | $ 66.18 | -3.17 % | $ 1.86 B |  Costa-rica |